ライフサイエンスコーパス: glycogen synthase kinase 3

1 a manner that depends on phosphorylation by glycogen synthase kinase 3.

2 by an Ebp2 degron that is phosphorylated by glycogen synthase kinase 3.

3 vated protein kinase (Erk1/2) cascade and of glycogen synthase kinase 3.

4 ase and cyclin-dependent kinase families and glycogen synthase kinase 3.

5 blast growth factor (FGF)/Erk pathway and of glycogen synthase kinase 3.

6 these motifs in the endogenous LRP6 through glycogen synthase kinase 3.

7 se A and subsequently by casein kinase 1 and glycogen synthase kinase 3.

8 sphorylation of adjacent casein kinase 1 and glycogen synthase kinase 3.

9 ytosis enzyme dynamin I via an inhibition of glycogen synthase kinase 3.

10 termined by phosphorylation of its substrate glycogen synthase kinase-3.

11 lation primes for Ser-159 phosphorylation by glycogen synthase kinase-3.

12 (+) NPCs with a pharmacological inhibitor of glycogen synthase kinase 3, a known regulator of WNT sig

13 activated calcitonin receptor phosphorylated glycogen synthase kinase-3, a key regulator of cytosolic

14 racellular signal regulated kinase (ERK) and glycogen synthase kinase-3 activation, indicating their

15 l requirement of canonical Wnt signaling and glycogen synthase kinase 3 activity for MLL fusion oncog

16 : it increases Akt phosphorylation, inhibits glycogen synthase kinase 3 activity, reduces IkappaB pho

17 hatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism o

18 ogenesis, immunomodulation and regulation of glycogen synthase kinase-3 activity.

19 E-cadherin, and CD44-mediated signaling and glycogen synthase kinase-3/adenomatous polyposis coli-me

20 Acute responses of ERK1/2, p38, Akt, and glycogen synthase kinase 3 after mechanical stress were

21 ited S6 kinase, protein kinase Cepsilon, and glycogen synthase kinase 3 alpha and beta.

22 rylation of AKT and expression of the kinase glycogen synthase kinase-3 alpha (GSK3-alpha) was also m

23 way activation, enhanced CGNP proliferation, glycogen synthase kinase-3 alpha/beta (GSK-3 alpha/beta)

24 s of the beta-catenin "destruction complex," glycogen synthase kinase 3 and beta-transducin repeat co

25 through a signaling mechanism that requires glycogen synthase kinase 3 and DVL.

26 from the nucleus after rephosphorylation by glycogen synthase kinase 3 and other kinases.

27 nd that their phosphorylation is mediated by glycogen synthase kinase 3 and PKA kinases.

28 esenchymal progenitors through inhibition of glycogen synthase kinase 3 and stabilization of beta-cat

29 axons in vitro, including two inhibitors of glycogen synthase kinase 3 and two inhibitors of IkappaB

30 ent reports that suggest a possible role for glycogen synthase kinase 3 and upstream wingless (Wnt)-f

31 lian target of rapamycin signaling, glucose, glycogen synthase kinase-3 and liver kinase B1, protein

32 ardiomyocytes in early developmental stages, glycogen synthase kinase-3 and p38 mitogen-activated pro

33 kt activation, a pathway known to inactivate glycogen synthase kinase-3 and reduce tau phosphorylatio

34 (G6P) and reversible phosphorylation through glycogen synthase kinase-3 and the glycogen-associated f

35 in sensitivity likely through increased Akt, glycogen synthase kinase 3, and AMPK phosphorylation; an

36 ting in the "destruction complex" with Axin, glycogen synthase kinase 3, and casein kinase, APC targe

37 P); and three NFAT kinases, casein kinase 1, glycogen synthase kinase 3, and dual specificity tyrosin

38 ing pathways (protein kinase A/DARPP-32, Akt/glycogen synthase kinase 3, and ERK) are involved in the

39 l, the effects of insulin on Akt activation, glycogen synthase kinase 3, and FoxO1a phosphorylation,

40 m from p38 mitogen-activated protein kinase, glycogen synthase kinase 3, and insulin-like receptor pa

41 ctivation of the proapoptotic proteins FKHR, glycogen synthase kinase-3, and Bad, which are events in

42 s of the brassinosteroid (BR) signaling, the glycogen synthase kinase 3/Arabidopsis SHAGGY-like kinas

43 evealed increased phosphorylation of AKT and glycogen synthase kinase 3 beta (GSK-3beta) in both the

44 Glycogen synthase kinase 3 beta (GSK-3beta) is a central

45 mmalian kinases, we found that inhibitors of glycogen synthase kinase 3 beta (GSK-3beta) protected ce

46 The BCR attenuates glycogen synthase kinase 3 beta (GSK3beta) activity to s

47 , axin2, were significantly reduced, whereas glycogen synthase kinase 3 beta (GSK3beta) and phospho-b

48 The ubiquitous serine/threonine kinase glycogen synthase kinase 3 beta (Gsk3beta) differentiall

49 Glycogen synthase kinase 3 beta (GSK3beta) is a critical

50 Glycogen synthase kinase 3 beta (GSK3beta) is highly ina

51 We identify an interaction of BMP and Wnt/glycogen synthase kinase 3 beta (GSK3beta) pathways via

52 ral studies in rodent models have shown that glycogen synthase kinase 3 beta (GSK3beta) plays an impo

53 dulate the activity of Tankyrase enzymes and glycogen synthase kinase 3 beta (GSK3beta), additional t

54 way involving protein phosphatase 2A (PP2A), glycogen synthase kinase 3 beta (GSK3beta), and their do

55 activator of smoothened, and phosphorylated glycogen synthase kinase 3 beta (pGSK-3B), an inactive f

56 ed activation of Wnt signaling via the Wnt3a/glycogen synthase kinase 3 beta axis.

57 aggregates was investigated by coexpressing glycogen synthase kinase 3 beta or microtubule-associate

58 on on Ser(552), a site that differs from the glycogen synthase kinase 3 beta phosphorylation site.

59 cells led to an increase of pS(9)-GSK3beta (glycogen synthase kinase 3 beta) compared with kinase-de

60 ibition of the pro-apoptotic molecules, JNK, glycogen synthase kinase 3 beta, or caspases, toxicity i

61 hosphorylation of direct downstream targets (glycogen synthase kinase 3 beta, proline-rich Akt substr

62 Glycogen synthase kinase-3 beta (GSK-3beta) is overexpre

63 Next, we apply this strategy to study glycogen synthase kinase-3 beta (GSK-3beta), a kinase ab

64 The present experiments examine changes in glycogen synthase kinase-3 beta (Gsk-3beta), and transcr

65 sphorylation (p-) of STAT5, ERK1/2, AKT, and glycogen synthase kinase-3 beta, and increased AKT enzym

66 AT5, but minimal induction of p-ERK1/2 and p-glycogen synthase kinase-3 beta.

67 ognition and phosphorylation of cyclin D1 by glycogen synthase kinase-3 beta.

68 ent (CTF), insulin receptor, IGF-1 receptor, glycogen synthase kinase 3-beta (GSK-3beta), protein kin

69 In this study, we demonstrate glycogen synthase kinase 3-beta (GSK3-beta) plays a fund

70 ding protein Axin and its associated kinase, glycogen synthase kinase 3-beta (GSK3-beta).

71 y treating SH-SY5Y cells with inhibitors for glycogen synthase kinase 3-beta (GSK3beta) and cyclin-de

72 Insulin/GSK-3beta (glycogen synthase kinase 3-beta) signalling induces cycl

73 TA accelerated beta-catenin degradation by a glycogen synthase kinase 3-beta-dependent mechanism.

74 vators p35 and p25, and pY216 phosphorylated glycogen synthase kinase 3-beta.

75 evealed a role for heat shock protein 90 and glycogen synthase kinase 3 but not casein kinase 1 nor L

76 n or inhibition of the Akt downstream target glycogen synthase kinase 3 by its pharmacologic inhibito

77 Additional inhibition of glycogen synthase kinase 3 consolidates biosynthetic cap

78 in kinase and the Akt-mediated inhibition of glycogen synthase kinase 3, critical inhibitors of Smad

79 lations of AMPK, acetyl CoA carboxylase, and glycogen synthase kinase-3, decreased glycogen synthase

80 hRspo1 induces glycogen synthase kinase 3-dependent phosphorylation and

81 drogenase kinase-1, or its downstream target glycogen synthase kinase-3 did not prevent CCR9 expressi

82 ars has helped define the role of the GSK-3 (glycogen synthase kinase-3) family in a variety of physi

83 It has been suggested that glycogen synthase kinase 3 (GSK-3) acts as an integratin

84 PGE(2) inactivated glycogen synthase kinase 3 (GSK-3) and promoted nuclear

85 uclear antigen (LANA) protein interacts with glycogen synthase kinase 3 (GSK-3) and relocalizes GSK-3

86 interaction with the serine-threonine kinase glycogen synthase kinase 3 (GSK-3) and stabilization of

87 , we found that small molecule inhibitors of glycogen synthase kinase 3 (GSK-3) consistently caused a

88 Like lithium, glycogen synthase kinase 3 (GSK-3) inhibitors display bo

89 phosphorylation of C/EBP beta was blocked by glycogen synthase kinase 3 (GSK-3) inhibitors, suggestin

90 Here we show that glycogen synthase kinase 3 (GSK-3) interacts with and ph

91 Emerging evidence has suggested that glycogen synthase kinase 3 (GSK-3) is a key regulatory k

92 Glycogen synthase kinase 3 (GSK-3) is a major kinase imp

93 In this work, we sought to determine if glycogen synthase kinase 3 (GSK-3) is important for ET-i

94 ing evidence suggests that the regulation of glycogen synthase kinase 3 (GSK-3) might be important in

95 The conserved glycogen synthase kinase 3 (GSK-3) phosphorylation site

96 Here, we report that glycogen synthase kinase 3 (GSK-3) was required for Mcl-

97 a-catenin pathway through phosphorylation of glycogen synthase kinase 3 (GSK-3), suggesting that this

98 sufficient to mediate the phosphorylation of glycogen synthase kinase 3 (GSK-3).

99 hosphorylation of this site is identified as glycogen synthase kinase 3 (GSK-3).

100 racellular signal-regulated kinase (ERK) and glycogen synthase kinase 3 (GSK-3).

101 Glycogen synthase kinase 3 (GSK-3, isoforms alpha and be

102 ne/threonine protein kinase PIM1 (PIM-1) and glycogen synthase kinase 3 (GSK-3beta) are inhibited wit

103 beta-Catenin/Glycogen synthase kinase 3 (GSK-3beta) association and b

104 Glycogen synthase kinase 3 (GSK-3beta) serine phosphoryl

105 ugh alpha-catenin and the kinase activity of glycogen synthase kinase 3 (GSK-3beta).

106 ) DC resulted from failed down-regulation of glycogen synthase kinase-3 (GSK-3) activity and could no

107 h increased and decreased by manipulation of glycogen synthase kinase-3 (GSK-3) activity.

108 Increasing attention is being focused on Akt/glycogen synthase kinase-3 (GSK-3) and wingless (Wnt) si

109 inositol biosynthetic pathway and the enzyme glycogen synthase kinase-3 (GSK-3) are targets of the mo

110 Glycogen synthase kinase-3 (GSK-3) exists as two structu

111 The glycogen synthase kinase-3 (GSK-3) family of serine/thre

112 The glycogen synthase kinase-3 (GSK-3) family of serine/thre

113 The glycogen synthase kinase-3 (GSK-3) has been linked to th

114 Based on extensive preclinical data, glycogen synthase kinase-3 (GSK-3) has been proposed to

115 response, and we isolated a mutation in the glycogen synthase kinase-3 (GSK-3) homolog Shaggy.

116 The role of glycogen synthase kinase-3 (GSK-3) in Alzheimer disease

117 In this report, we studied the role of glycogen synthase kinase-3 (GSK-3) inactivation on neuri

118 The challenge for glycogen synthase kinase-3 (GSK-3) inhibitor design lies

119 Lithium, a glycogen synthase kinase-3 (GSK-3) inhibitor, and VPA, a

120 Combining glycogen synthase kinase-3 (GSK-3) inhibitors with VPA o

121 Glycogen synthase kinase-3 (GSK-3) is a constitutively a

122 Glycogen synthase kinase-3 (Gsk-3) is a key regulator of

123 Glycogen synthase kinase-3 (GSK-3) is a key regulator of

124 Glycogen synthase kinase-3 (GSK-3) is a master regulator

125 Cumulative evidence strongly supports that glycogen synthase kinase-3 (GSK-3) is a pathogenic molec

126 Glycogen synthase kinase-3 (GSK-3) is a serine/threonine

127 Glycogen synthase kinase-3 (GSK-3) is a serine/threonine

128 Glycogen synthase kinase-3 (GSK-3) is essential for many

129 Glycogen synthase kinase-3 (GSK-3) is increasingly recog

130 Glycogen synthase kinase-3 (GSK-3) is linked to the path

131 We report that the activity of glycogen synthase kinase-3 (GSK-3) is necessary for the

132 Glycogen synthase kinase-3 (GSK-3) is one of the few sig

133 Glycogen synthase kinase-3 (GSK-3) isoforms, GSK-3alpha

134 Glycogen synthase kinase-3 (Gsk-3) isoforms, Gsk-3alpha

135 in the absence of stress, phosphorylation by glycogen synthase kinase-3 (GSK-3) prevents SKN-1 from a

136 We report here that specific inhibition of glycogen synthase kinase-3 (GSK-3) reduces tau phosphory

137 Glycogen synthase kinase-3 (GSK-3) regulates multiple ce

138 de et al. uses phosphoproteomics to identify glycogen synthase kinase-3 (GSK-3) substrates in mouse e

139 atment of cells with a specific inhibitor of glycogen synthase kinase-3 (GSK-3), a downstream effecto

140 andidates include inositol monophosphatases, glycogen synthase kinase-3 (GSK-3), and a beta-arrestin-

141 We investigated the role of glycogen synthase kinase-3 (GSK-3), which is inactivated

142 DydA is phosphorylated by glycogen synthase kinase-3 (GSK-3), which is required fo

143 together with inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3), which relieves its i

144 Predictably, inhibition of glycogen synthase kinase-3 (GSK-3), which results from a

145 FRAT1, like its Xenopus homolog glycogen synthase kinase-3 (GSK-3)-binding protein, is k

146 hanism by which HIF-1alpha is degraded after glycogen synthase kinase-3 (GSK-3)-induced phosphorylati

147 n of Akt and phosphorylation-inactivation of glycogen synthase kinase-3 (GSK-3).

148 gents to determine whether the regulation of glycogen synthase kinase-3 (GSK-3)/beta-catenin and mTOR

149 ling events that result in the inhibition of glycogen synthase kinase-3 (GSK-3)beta represent an adap

150 The Drosophila homolog of glycogen synthase kinase-3 (GSK-3)beta, Shaggy, is requi

151 ce containing a mutant constitutively active glycogen synthase kinase-3 (GSK-3beta) transgene, driven

152 Suppression of glycogen synthase kinase 3 (GSK3) activity in neurons yi

153 nonical Wnt signaling requires inhibition of Glycogen Synthase Kinase 3 (GSK3) activity, but the mole

154 ignalling pathway or dual inhibition (2i) of glycogen synthase kinase 3 (Gsk3) and mitogen-activated

155 We show that glycogen synthase kinase 3 (GSK3) and protein arginine m

156 cells due to its constant phosphorylation by glycogen synthase kinase 3 (GSK3) and subsequent proteas

157 hosphorylation at Thr41, Ser37, and Ser33 by glycogen synthase kinase 3 (GSK3) and that phosphorylate

158 Inhibitors of glycogen synthase kinase 3 (GSK3) are being explored as

159 kinases cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3 (GSK3) at sites that are hype

160 by casein kinase 1 at the Ser-45 site and by glycogen synthase kinase 3 (GSK3) at the Thr-41, Ser-37,

161 Here we show how inhibiting glycogen synthase kinase 3 (GSK3) can improve the differ

162 ition of protein kinase C-beta (PKCbeta) and glycogen synthase kinase 3 (GSK3) causes synergistic apo

163 ation of a serine (S373A) in CIITA, within a glycogen synthase kinase 3 (GSK3) consensus site, decrea

164 ng approaches, we show how the activation of glycogen synthase kinase 3 (GSK3) contributes to neurona

165 Here we report that glycogen synthase kinase 3 (GSK3) differentially regulat

166 (288), and Tyr(277) by Mck1, a kinase of the glycogen synthase kinase 3 (Gsk3) family.

167 differentiation through negatively affecting glycogen synthase kinase 3 (GSK3) function.

168 Herein, we investigated the role of glycogen synthase kinase 3 (GSK3) in liver regeneration

169 Appropriate temporal application of a glycogen synthase kinase 3 (GSK3) inhibitor combined wit

170 nd this phosphorylation was inhibited by the glycogen synthase kinase 3 (GSK3) inhibitor indirubin-3'

171 Glycogen synthase kinase 3 (GSK3) inhibitors were identi

172 Here we report that glycogen synthase kinase 3 (GSK3) inhibits AMPK function

173 ly that Wnt-induced Lrp6 phosphorylation via glycogen synthase kinase 3 (Gsk3) initiates Wnt/beta-cat

174 Glycogen synthase kinase 3 (GSK3) is a critical enzyme i

175 Glycogen synthase kinase 3 (GSK3) is a genetically valid

176 Glycogen synthase kinase 3 (GSK3) is a highly conserved

177 Here we show that glycogen synthase kinase 3 (Gsk3) is a metabolic sensor

178 Glycogen synthase kinase 3 (GSK3) is a multifunctional s

179 Glycogen synthase kinase 3 (GSK3) is a widely expressed

180 Phosphorylation of glycogen synthase kinase 3 (GSK3) isoforms alpha/beta by

181 has been associated with altered activity of glycogen synthase kinase 3 (GSK3) isozymes, which are pr

182 phosphodegron (CPD) signal, a target site of glycogen synthase kinase 3 (GSK3) kinase and Fbw7 ubiqui

183 Previous studies have indicated that glycogen synthase kinase 3 (GSK3) may play a role in APP

184 We also demonstrate that the kinase glycogen synthase kinase 3 (GSK3) mediates the FBW7-depe

185 Here, we show the expression of the Glycogen synthase kinase 3 (GSK3) MoGSK1 in M. oryzae is

186 we demonstrate a potent effect of inhibiting glycogen synthase kinase 3 (GSK3) on definitive endoderm

187 lt gastric epithelium via deletion of either glycogen synthase kinase 3 (GSK3) or APC or via expressi

188 Suppression of glycogen synthase kinase 3 (GSK3) or FBXW7 rescued Mcl-1

189 cyclin-dependent kinase 1 (cdk1 [cdc2]) and glycogen synthase kinase 3 (GSK3) pathways as two probab

190 ation mediated by a phosphodegron created by glycogen synthase kinase 3 (GSK3) phosphorylation of Mcl

191 PX-866 treatment abolished AKT/glycogen synthase kinase 3 (GSK3) phosphorylation, and c

192 n target of rapamycin complex 1 (mTORC1) and glycogen synthase kinase 3 (GSK3) play pivotal roles in

193 Glycogen synthase kinase 3 (GSK3) plays a central role i

194 RECENT FINDINGS: Glycogen synthase kinase 3 (GSK3) plays a critical role

195 This investigation found that glycogen synthase kinase 3 (GSK3) promotes apoptotic sig

196 We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-beta

197 schizophrenia, and depression, regulates Akt/glycogen synthase kinase 3 (GSK3) signaling and related

198 itor pools and plays a key role in mediating glycogen synthase kinase 3 (GSK3) signaling during brain

199 Here, we report that Wnt/glycogen synthase kinase 3 (GSK3) signaling functions po

200 Multisite phosphorylation of glycogen synthase kinase 3 (GSK3) sites near the EB1 bin

201 ted AMP-activated protein kinase (AMPK), and glycogen synthase kinase 3 (GSK3) underwent Western blot

202 molecule inhibition of MAP kinase (MEK) and glycogen synthase kinase 3 (GSK3) with LIF (2i/LIF) prov

203 Glycogen synthase kinase 3 (GSK3), a key component of th

204 Glycogen synthase kinase 3 (GSK3), a prominent enzyme in

205 n in DRG neurons leads to phosphorylation of glycogen synthase kinase 3 (GSK3), a protein that normal

206 Glycogen synthase kinase 3 (GSK3), a serine/threonine ki

207 clock proteins by casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3), appear conserved amon

208 n kinase A (PKA), casein kinase 1 (CK1), and glycogen synthase kinase 3 (GSK3), as well as the activi

209 There are two subtypes of glycogen synthase kinase 3 (GSK3), GSK3 alpha and GSK3 b

210 such as cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3 (GSK3), has been implicated i

211 kt inhibition was abrogated by inhibitors of glycogen synthase kinase 3 (GSK3), implying that the cen

212 ating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microt

213 Moreover, we show that glycogen synthase kinase 3 (GSK3), rather than mammalian

214 Here, we report synergistic inhibition of glycogen synthase kinase 3 (GSK3), transforming growth f

215 Glycogen synthase kinase 3 (GSK3), which is known for it

216 Lithium is a potent inhibitor of glycogen synthase kinase 3 (GSK3), which regulates circa

217 PI3K and Akt1 that resulted in repression of glycogen synthase kinase 3 (GSK3)-beta activity.

218 phosphorylation of VEGFR2, MAP kinases, and glycogen synthase kinase 3 (GSK3)-beta.

219 ng inhibits stomatal development through the glycogen synthase kinase 3 (GSK3)-like kinase BIN2, and

220 Moreover, MYBL2 is a substrate of glycogen synthase kinase 3 (GSK3)-like kinase brassinost

221 gers a rapid lack of VDAC phosphorylation by glycogen synthase kinase 3 (GSK3).

222 ed that RNPC1 is phosphorylated at Ser195 by glycogen synthase kinase 3 (GSK3).

223 ions as cyclin-dependent kinase 5 (CDK5) and glycogen synthase kinase 3 (GSK3).

224 containing the negative regulators Axin and glycogen synthase kinase 3 (GSK3).

225 ents, including dishevelled (Dvl), axin, and glycogen synthase kinase 3 (GSK3).

226 e protein kinase shaggy, the fly ortholog of glycogen synthase kinase 3 (GSK3).

227 mine analogues which are inhibitors of human glycogen synthase kinase 3 (GSK3).

228 after essential phosphorylations by MAPK and glycogen synthase kinase 3 (GSK3).

229 mitochondrial respiratory quiescence through glycogen synthase kinase 3 (GSK3).

230 trate that this residue is phosphorylated by glycogen synthase kinase 3 (GSK3).

231 inases, among them casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3).

232 yrazol-3-ylquinazolin-4-ylamine inhibitor of glycogen synthase kinase 3 (GSK3).

233 stabilizing many proteins phosphorylated by glycogen synthase kinase 3 (GSK3).

234 diated degradation due to phosphorylation by glycogen synthase kinase 3 (Gsk3).

235 We show that this process is dependent on glycogen synthase kinase 3 (GSK3): GSK3 was associated w

236 Intriguingly, glycogen synthase kinase-3 (GSK3) acts centrally, likely

237 ositol-3 kinase/Akt (IRS-PI3K-Akt) pathways, glycogen synthase kinase-3 (GSK3) and mammalian target o

238 T3 signaling, and simultaneous inhibition of glycogen synthase kinase-3 (GSK3) and MAP kinase/ERK kin

239 Glycogen synthase kinase-3 (GSK3) are ubiquitously expre

240 plementary signaling pathways and identified glycogen synthase kinase-3 (GSK3) as important in surviv

241 s to Th17 cells, we found that inhibition of glycogen synthase kinase-3 (GSK3) blocked IL-6 productio

242 haracterize a novel activation mechanism for glycogen synthase kinase-3 (GSK3) by the sphingolipids p

243 In this study, we identified that glycogen synthase kinase-3 (GSK3) differentially regulat

244 The glycogen synthase kinase-3 (GSK3) family kinases are cen

245 In just a few years, the view of glycogen synthase kinase-3 (GSK3) has been transformed f

246 The Axin scaffold and associated glycogen synthase kinase-3 (GSK3) have central roles in

247 he phosphorylation and activities of Akt and glycogen synthase kinase-3 (GSK3) in peripheral tissues,

248 Phosphorylation of the PI3K effector glycogen synthase kinase-3 (GSK3) in the absence of PI3K

249 Treatment with lithium or a glycogen synthase kinase-3 (GSK3) inhibitor corrects beh

250 ia containing fetal bovine serum (FBS) and a glycogen synthase kinase-3 (GSK3) inhibitor, and in seru

251 Glycogen synthase kinase-3 (GSK3) is a constitutively ac

252 Here, we report that glycogen synthase kinase-3 (GSK3) is a critical determin

253 Glycogen synthase kinase-3 (GSK3) is a highly conserved

254 Hippocampal glycogen synthase kinase-3 (GSK3) is hyperactive in the

255 gated the effect of inhibitors targeting the glycogen synthase kinase-3 (GSK3) on the expression of N

256 Moreover, induction of glycogen synthase kinase-3 (GSK3) performed using a Wnt

257 f-function approaches in mice, we found that glycogen synthase kinase-3 (Gsk3) plays a pivotal role i

258 Glycogen synthase kinase-3 (GSK3) regulates many physiol

259 Inhibition of glycogen synthase kinase-3 (Gsk3) supports mouse embryon

260 ependent phosphorylation and inactivation of glycogen synthase kinase-3 (GSK3), an enzyme that regula

261 nvestigated whether lithium, an inhibitor of glycogen synthase kinase-3 (GSK3), can ameliorate EAE in

262 nation through Akt-independent inhibition of glycogen synthase kinase-3 (GSK3), itself a candidate th

263 rrent study, we tested whether inhibitors of glycogen synthase kinase-3 (GSK3), previously reported t

264 ivation of the constitutively active enzyme, glycogen synthase kinase-3 (GSK3), which has been implic

265 ivity in an adenomatous polyposis coli (APC)/glycogen synthase kinase-3 (GSK3)-independent manner, re

266 that STAT3 activation is highly dependent on glycogen synthase kinase-3 (GSK3).

267 In the present study, we identify that glycogen-synthase kinase 3 (GSK3) regulates the producti

268 egulated cytoskeletal-associated protein and glycogen-synthase kinase 3 (GSK3).

269 way seems to occur from Dishevelleds to axin/glycogen synthase kinase 3(GSK3)/beta-catenin complexes

270 level of protein stability and controlled by glycogen synthase kinase 3 in a cyclic AMP-protein kinas

271 he neighboring Ser-208, the priming site for glycogen synthase kinase 3 in vivo activity, strengthene

272 blocked cardiomyocyte specification, whereas glycogen synthase kinase 3 inhibition at this point enha

273 nt which was suppressed by co-treatment with glycogen synthase kinase 3 inhibitor SB216763.

274 thermore, sequential treatment of hPSCs with glycogen synthase kinase 3 inhibitors followed by induci

275 g research results involving ethyl pyruvate, glycogen synthase kinase-3 inhibitors and 3-hydroxy-3-me

276 phosphorylated by recombinant GSK3beta; and glycogen synthase kinase-3 inhibitors effectively reduce

277 novel bi-directionality in the AKT and GSK3 (Glycogen synthase kinase 3) interaction, whereby genetic

278 addition to the two C-terminal residues, and glycogen synthase kinase 3 is responsible for phosphoryl

279 Glycogen synthase kinase-3 is a Ser/Thr kinase, tonicall

280 enhanced risk for SZ and/or BD can activate glycogen synthase kinase-3 isozymes (GSK3alpha and beta)

281 phorylation markedly enhances the binding of glycogen synthase kinase 3, leading to a more active bet

282 re is restoration of phospho-Akt and phospho-glycogen synthase kinase 3 levels in the treated mice, c

283 an be phosphorylated and stabilized by GSK3 (GLYCOGEN SYNTHASE KINASE 3)-like kinase BIN2 (BRASSINOST

284 through a signalling pathway that involves a glycogen synthase kinase-3-like kinase (BIN2) and a seri

285 lthough JNK activity is not required for the glycogen synthase kinase-3-mediated degradation of beta-

286 ellular signal-regulated kinase pathway, the glycogen synthase kinase-3-mediated pathway and Bcl-2 ar

287 ell; PI3K, phosphoinositide 3-kinases; GSK3, glycogen synthase kinase-3; mTOR, mammalian target of ra

288 The glycogen synthase kinase-3 of the parasite (PfGSK-3) was

289 inhibition of Janus kinase 1, inhibition of Glycogen synthase kinase 3, or addition of NRG1 signific

290 ed 4 chemical compound groups: inhibitors of glycogen synthase kinase-3, p38 mitogen-activated protei

291 (nuc)) with serine-to-alanine changes at the glycogen synthase kinase 3 phosphorylation sites.

292 I cells with chemical inhibitors of MEKs and glycogen synthase kinase 3 resulted in their further rep

293 to ERK1/2 and Akt, including p70 S6-kinase, glycogen synthase kinase-3, ribosomal S6 kinase, c-Jun,

294 Our data reveal that glycogen synthase kinase 3 signaling also regulates eEF2

295 hium chloride, a reversible inhibitor of the glycogen synthase kinase-3, that rescued NMJ defects in

296 Inhibition of glycogen synthase kinase-3 was able to abolish IES-induc

297 Pharmacological inhibition of glycogen synthase kinase-3 was sufficient to reverse the

298 , while application of Bikinin (inhibitor of glycogen synthase kinase-3), which activated BR signalin

299 to their ability to serve as substrates for glycogen synthase kinase 3, which acts at neighboring N-

300 Insulin is a well-known inhibitor of glycogen synthase kinase-3, which may play an important